Riskpilot← Back to searchSign inGet full accessAnnexin Pharmaceuticals AB (publ)
ABActiveOrg 5569609539Kammakargatan 48Manufacture of pharmaceutical preparations · NACE 2120Est. 20145-9 employees
Revenue 2024
SEK 0
EBITDA margin
—
-14% vs 2023
Equity ratio
72.0%
Financial strength
Net profit 2024
SEK -50,3M
-14% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -50,5M | -14% |
| Net profit | SEK -50,3M | -14% |
| Total assets | SEK 19M | -29% |
| Equity | SEK 13,7M | -27% |
| Employees | — | — |
Legal name
Annexin Pharmaceuticals AB (publ)
Org number
5569609539
Legal form
Aktiebolag
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
5 februari 2014
Share capital
SEK 8 821 000
Employees
5-9
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Firman tecknas av en av ledamöterna i förening med en av Andersson, Susanne Kristina Haegerstrand, Nils Anders Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Föremålet för bolagets verksamhet ska vara att utveckla läkemedel och medicintekniska produkter, att äga och förvalta aktier och andelar inom området för medicin, bioteknik, läkemedel och medicinteknink, samt bedriva därmed förenlig verksamhet.
Address
Kammakargatan 48
Phone
+46730668904
Email
investors@annexinpharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −43 737 | −51 233 | −40 724 | −44 176 | −50 480 |
| Depreciation & amort. | — | — | — | — | — |
| EBIT | −43 737 | −51 233 | −40 724 | −44 176 | −50 480 |
| Net financials | −503 | −909 | −2 | 122 | 229 |
| Profit before tax | −44 240 | −52 142 | −40 726 | −44 054 | −50 252 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −44 240 | −52 142 | −40 726 | −44 054 | −50 252 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 25 158 | 52 786 | 36 679 | 26 763 | 19 036 |
| Equity | 20 638 | 46 727 | 30 153 | 18 814 | 13 713 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 4 520 | 6 059 | 6 526 | 7 949 | 5 323 |
| Total debt | 4 520 | 6 059 | 6 526 | 7 949 | 5 323 |
EBITDA margin
-5048000000.0%
This company
15.8%
Market median
-31949367189% vs market
20202024
Equity ratio
72.0%
This company
38.2%
Market median
+88% vs market
20202024
Return on equity
-366.5%
This company
18.4%
Market median
-2092% vs market
20202024
Net profit margin
-5025200000.0%
This company
8.1%
Market median
-62039506273% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.39×
This company
0.62×
Market median
+37% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
BM Chief Auditor | Chief Auditor | 2020 |
NA Chief Executive Officer | Chief Executive Officer | 2020 |
SK External Signatory | External Signatory | 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2020 | |
| Board of Directors | 2020 | |
| Chairman | 2024 | |
| Board of Directors | 2024 | |
| Former (5) | ||
| Board of Directors | 2022 – 2024 | |
| Chairman | 2022 – 2024 | |
| Board of Directors | 2022 – 2024 | |
| Board of Directors | 2020 – 2022 | |
| Board of Directors | 2022 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Annexin Pharmaceuticals AB (publ) 
Annexin Incentive ABBoard members of Annexin Pharmaceuticals AB (publ) also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bo Magnus Lagerberg | Chief Auditor | 0 companies |
| Nils Anders Haegerstrand | Chief Executive Officer | 0 companies |
| Susanne Kristina Andersson | External Signatory | 0 companies |
| Carl-Fredrik Lyman Erik F Lindner | Board of Directors | 0 companies |
| Curt Mikael von Euler-Chelpin | Board of Directors | 0 companies |
| Gisela Marie Sitbon | Board of Directors | 0 companies |
| Nils Jan Ragnar Nilsson | Chairman | 0 companies |
| Erik Olof Mikael Lönn | Board of Directors | 0 companies |
| Uli Alf Hacksell | Chairman | 0 companies |
| Dan Mårten Österlund | Board of Directors | 0 companies |
| Lena Margareta Torlegård | Board of Directors | 0 companies |
| Olof Anthon Jahreskog | Board of Directors | 0 companies |